Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
oxaliplatine/ gemcitabine/ Vinorelbine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| oxaliplatine / gemcitabine / Vinorelbine | DRUG | - |
Inclusion Criteria: * Non-small cell bronchopulmonary cancer established by histological and/or cytological methods; * Advanced or metastatic disease (stage IIIB or IV); * At least one measurable lesion with one dimension (\>= 20 mm by CT scan or \>=10 mm by CT scan) outside of the irradiated area;...
Top 20 of 90 competitors
This combination regimen was studied for Non Small Cell Lung Cancer. It combines three small molecule chemotherapy agents: oxaliplatine, gemcitabine, and Vinorelbine. The regimen was evaluated in a Phase 2 trial conducted in France in adults aged 18 years and older.
Sanofi, which trades under the ticker SNY, is the developer associated with this oxaliplatine, gemcitabine, and Vinorelbine combination regimen for Non Small Cell Lung Cancer. The program was studied in a single Phase 2 clinical trial.
Oxaliplatine/gemcitabine/Vinorelbine is in Phase 2 development for Non Small Cell Lung Cancer. The one registered trial for this combination, NCT00271271, has completed. It is an investigational regimen and is not described as approved.
The regimen was studied in NCT00271271, titled Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients. This Phase 2 trial enrolled 40 participants with Non Small Cell Lung Cancer in France. It was an uncontrolled, non-randomized, open-label study in adults aged 18 years and older, and it has completed.
Oxaliplatine/gemcitabine/Vinorelbine has been studied in one registered clinical trial, NCT00271271, which is completed. That Phase 2 study enrolled 40 participants with Non Small Cell Lung Cancer in France and used an uncontrolled design without randomization or blinding.